Tirzepatide

Tirzepatide is a real, regulated drug with clinical trial data behind its approved uses, available only by prescription. This page describes its approved uses and standard prescribing information — that's public medical information about a regulated drug, not personalized medical advice. Talk to your doctor about whether it's appropriate for you.

Tirzepatide is a synthetic peptide that activates both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors — a dual mechanism, unlike semaglutide's single GLP-1 action. Activating both pathways together produces glucose-dependent insulin release, appetite suppression, and slower gastric emptying, and has shown somewhat larger average weight-loss and blood-sugar effects than single-pathway GLP-1 drugs in head-to-head trials.

Mounjaro — glycemic control in adults with type 2 diabetes, alongside diet and exercise.

Zepbound — chronic weight management in adults with obesity or overweight plus a weight-related condition, alongside diet and exercise, and for moderate-to-severe obstructive sleep apnea in adults with obesity. Unlike semaglutide, tirzepatide does not currently carry an FDA-approved cardiovascular-risk-reduction indication.

Mayo Clinic — Tirzepatide (Subcutaneous Route) →

Like semaglutide, tirzepatide starts at a low, non-therapeutic dose (2.5mg weekly) to ease GI onset, then steps up roughly every 4 weeks toward a therapeutic maintenance dose your prescriber sets based on your response and indication. This is general public prescribing information, not a personalized recommendation.

Tirzepatide carries the same FDA boxed warning as semaglutide for thyroid C-cell tumors seen in rodent studies, and is contraindicated with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Other risks include pancreatitis, gallbladder disease, severe GI disease, hypoglycemia when combined with insulin or sulfonylureas, and acute kidney injury. Common side effects are gastrointestinal, especially during dose increases.

Mayo Clinic — Tirzepatide (Subcutaneous Route)